Recent Updates — CLYD

Beacon Topco, Inc., Barinthus Biotherapeutics plc, and Clywedog Therapeutics entered into a Third Amendment to their Merger Agreement on October 31, 2026. The amendment restates the closing timeline, requiring the transaction to close by November 13, 2026, and updates the definition of the "End Date" accordingly. This follows previous amendments dated February 22 and September 22, 2026, and the acquisition of Beacon's share capital via a scheme of arrangement approved in September. The deal involves Merger Sub merging with Clywedog, which will continue as a wholly owned subsidiary of Topco. Beacon Topco operates in the biotechnology sector.

Beacon Topco, Inc. filed a Current Report on Form 8-K disclosing the Second Amendment to its Merger Agreement with Clywedog Therapeutics, Inc., which extends the closing date for the combination transaction to October 31, 2026. The filing also incorporates a joint press release announcing final results from Clywedog's Phase 1b study of balomenib in Type 2 Diabetes patients, showing sustained glycemic improvement and no serious adverse events. Beacon Topco operates as a holding company for biopharmaceutical assets.